Am J Perinatol 2025; 42(06): 758-767
DOI: 10.1055/a-2419-8916
Original Article

Maternal and Infant Morbidity and Mortality in Relation to Delivery Mode in a Large U.S. Health Care Claims Database in 2019 and 2020

1   Safety and Epidemiology, Carelon Research, Wilmington, Delaware
,
Stephanie Lynch
2   Clinical Research, Carelon Research, Wilmington, Delaware
,
Aneesh Naavaal
3   Anthem Health Solutions, Elevance Health, Indianapolis, Indiana
,
Chrissie Li
4   Health Economics, Elevance Health, Indianapolis, Indiana
,
Kimberly Cole
5   Clinical Analytics, Elevance Health, Indianapolis, Indiana
,
Leslie MacPhee
6   Healthcare Financial Analytics, Elevance Health, Indianapolis, Indiana
,
Leslie Banning
7   Health Solutions, Elevance Health, Indianapolis, Indiana
,
Anup Sharma
8   GA Medical Management, Elevance Health, Indianapolis, Indiana
,
Michael Grabner
9   Scientific Affairs, Carelon Research, Wilmington, Delaware
,
Eric Stanek
9   Scientific Affairs, Carelon Research, Wilmington, Delaware
,
Tiffany Inglis
10   Carelon MBM, Elevance Health, Indianapolis, Indiana
› Author Affiliations

Funding This study was funded by Elevance Health.
Preview

Abstract

Objective

This study aimed to provide contemporary data on maternal and infant outcomes after delivery to better understand risks of cesarean section (CS).

Study Design

Data for deliveries in 2019 and 2020 were obtained from a large U.S. commercial health care claims database. Maternal morbidity measures included 20 severe maternal morbidity (SMM) outcomes and seven additional obstetric and mental health outcomes. Infant morbidity measures included eight outcomes related to respiratory health, digestive health, atopic dermatitis, and birth trauma. Outcome prevalence was ascertained at 42 days (maternal only) and 360 days after delivery. Logistic regression was used to estimate the odds ratio (OR) and 95% confidence interval (CI) for prevalence adjusted for risk factors for delivery mode and each outcome. Analyses were conducted for 2019 and 2020 to assess the influence of the coronavirus disease 2019 pandemic.

Results

A total of 436,991 deliveries were identified (145,061 CS; 291,930 vaginal). The prevalence of SMM was 3.3% at 42 days and 4.1% at 360 days. The covariate-adjusted odds of SMM were higher among CS than vaginal deliveries at 42 days (OR: 2.0, 95% CI: 1.9, 2.1) and 360 days (OR: 1.7, 95% CI: 1.7, 1.8). There were 226,983 infants available for analysis of outcomes at 360 days. Most adverse infant outcomes were more prevalent at 360 days among CS than vaginal deliveries, and the covariate-adjusted odds of any adverse infant outcome at 360 days were higher among CS than vaginal deliveries (OR: 1.2; 95% CI: 1.1, 1.3). Respiratory morbidity was most affected by delivery mode. Maternal and infant mortality up to 360 days was rare. Similar trends were observed in the 2019 and 2020 cohorts.

Conclusion

This observational study, performed using recent data obtained from a large U.S. commercial claims database, provides contemporary evidence of risks to mothers and infants of CS relative to vaginal delivery.

Key Points

  • In a large commercially insured population, one-third of deliveries were by CS.

  • Most maternal and infant outcomes were more prevalent among CS deliveries than vaginal deliveries.

  • Respiratory conditions were most strongly related to delivery mode among infants.

  • Maternal and infant mortality up to 360 days was rare in this population.

  • Results were similar in 2019 and 2020, indicating a small impact of the COVID-19 pandemic.



Publication History

Received: 20 February 2024

Accepted: 20 September 2024

Accepted Manuscript online:
24 September 2024

Article published online:
29 October 2024

© 2024. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA